We are live on
!
Find out more
SCPH
scPharmaceuticals
SCPH
SCPH
Delisted
SCPH was delisted on the 6th of October, 2025.
26 hedge funds and large institutions have $44.5M invested in scPharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
89% more capital invested
Capital invested by funds: $23.5M → $44.5M (+$21M)
1.11% more ownership
Funds ownership: 39.67% → 40.78% (+1.1%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
16% less funds holding
Funds holding: 31 → 26 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Holders
26
Holders Change
-5
Holders Change %
-16.13%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$943K |
| 2 |
Renaissance Technologies
New York
|
+$376K |
| 3 |
JP Morgan Chase
New York
|
+$268K |
| 4 |
EP
Eversept Partners
New York
|
+$267K |
| 5 |
Morgan Stanley
New York
|
+$205K |
Top Sellers
| 1 |
Northern Trust
Chicago,
Illinois
|
-$317K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$126K |
| 3 |
Millennium Management
New York
|
-$108K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$96K |
| 5 |
SG Americas Securities
New York
|
-$41K |
